A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Clinical trial NCT04659785 · UNKNOWN
Trial details
- NCT number
- NCT04659785
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-01
- Primary completion
- 2021-07-31
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.